Bebo HealthXPAR:MLBBO 47 EBITDA Margin % is 20.26% as of Dec. 2025, which is 18% above its 10-year median of 17.19. GuruFocus rates XPAR:MLBBO with a GF Score™ of 47/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,124 Retail - Cyclical companies, Bebo Health ranks better than 85.23% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bebo Health's EBITDA for the
six
months ended in Dec. 2025 was €5.12 Mil. Bebo Health's Revenue for the
six
months ended in Dec. 2025 was €25.25 Mil. Therefore, Bebo Health's EBITDA margin for the quarter that ended in Dec. 2025 was 20.26%.
Bebo Health (XPAR:MLBBO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bebo Health EBITDA Margin % Related Terms
Bebo Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bebo Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MLBBO vs CASY, WSM, DKS: EBITDA Margin % Comparison
For the Specialty Retail subindustry, Bebo Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bebo Health EBITDA Margin % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Bebo Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bebo Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bebo Health (XPAR:MLBBO) has a EBITDA Margin % of 20.26% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bebo Health and its competitors. This is 18% above median its historical median of 17.19. Over the past decade, Bebo Health's EBITDA Margin % has ranged from 5.45 to 20.26. According to the industry distribution chart, Bebo Health ranks #166 out of 1124 companies in the Retail - Cyclical industry, placing it in the top 14.8%.
Is Bebo Health's EBITDA Margin % too high?
Bebo Health's current EBITDA Margin % of 20.26% is 18% above median its 10-year median of 17.19. Over the past 10 years, this metric has ranged from a low of 5.45 to a high of 20.26. The Retail - Cyclical industry median EBITDA Margin % is 7.50. Bebo Health's value of 20.26% is 170.1% above this industry median. Based on the distribution chart, Bebo Health ranks #166 out of 1124 companies in the Retail - Cyclical industry, which is in the top quartile — a strong position relative to peers. Overall, Bebo Health has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bebo Health's EBITDA Margin % compare to CASY and WSM?
According to the Retail - Cyclical industry distribution chart, Bebo Health ranks #166 out of 1124 companies for EBITDA Margin %. This places Bebo Health in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.50. Bebo Health's value of 20.26% is 170.1% above this benchmark. Historically, Bebo Health's own EBITDA Margin % has ranged from 5.45 to 20.26 over the past decade. While the company's 10-year median is 17.19 vs. the industry median of 7.50, Bebo Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Retail - Cyclical company?
The median EBITDA Margin % among Retail - Cyclical companies is 7.50, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bebo Health's current EBITDA Margin % of 20.26% is 170.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bebo Health and its competitors. For the Retail - Cyclical industry, the median EBITDA Margin % is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bebo Health's current EBITDA Margin % is 20.26%, which is 18% above median its own 10-year median of 17.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bebo Health stock overvalued right now?
Based on GuruFocus' analysis, Bebo Health (XPAR:MLBBO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.23 — trading 660% above its estimated fair value. The current EBITDA Margin % is 20.26%, which is 18% above median its 10-year median of 17.19 and 170.1% above the Retail - Cyclical industry median of 7.50. Bebo Health's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bebo Health (XPAR:MLBBO), the current EBITDA Margin % is 20.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bebo Health (XPAR:MLBBO) Overvalued in 2026?
Based on GuruFocus' analysis, Bebo Health stock appears to be overvalued.
The current stock price of €0.23 is trading 660% above its estimated GF Value™ of €0.03.
GuruFocus considers Bebo Health to be Significantly Overvalued.
Key valuation signals for XPAR:MLBBO:
EBITDA Margin %: 20.26% (18% above median its 10-year median of 17.19)
GF Value™: €0.03 vs. price of €0.23 (660% above fair value)
Industry Position: 170.1% above the Retail - Cyclical median (#166 of 1124)
No single metric tells the full story. See the XPAR:MLBBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBBO has been successfully added to your 